Karyopharm Therapeutics Inc
F:25K
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Karyopharm Therapeutics Inc
F:25K
|
US |
|
S
|
Steppe Cement Ltd
OTC:SPPCF
|
MY |
|
H
|
Hisense Home Appliances Group Co Ltd
XMUN:GKE
|
CN |
|
A
|
Axon Enterprise Inc
XMUN:TCS
|
US |
|
N
|
Novo Nordisk A/S
XMUN:NOV
|
DK |
|
Technip Energies NV
F:68F
|
FR |
|
S
|
Southern Copper Corp
F:PCU
|
US |
|
Bank Rakyat Indonesia (Persero) Tbk PT
OTC:BKRKY
|
ID |
|
Becle SAB de CV
F:6BE
|
MX |
|
B
|
Barco NV
F:BC1P
|
BE |
|
Celestial Asia Securities Holdings Ltd
F:CE0
|
HK |
|
W
|
WT Microelectronics Co Ltd
TWSE:3036A
|
TW |
|
Independence Realty Trust Inc
F:5O2
|
US |
|
A
|
ASM International NV
SWB:AVS
|
NL |
|
C
|
Corebridge Financial Inc
NYSE:CRBG
|
US |
|
New Oriental Education & Technology Group Inc
LSE:0K75
|
CN |
Wall St Price Targets
25K Price Targets Summary
Karyopharm Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for 25K is 6.58 EUR with a low forecast of 3.4 EUR and a high forecast of 8.08 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 25K's stock price target?
Price Target
6.58
EUR
According to Wall Street analysts, the average 1-year price target for 25K is 6.58 EUR with a low forecast of 3.4 EUR and a high forecast of 8.08 EUR.
What is the Revenue forecast for Karyopharm Therapeutics Inc?
Projected CAGR
17%
Over the last 13 years, the compound annual growth rate for Revenue has been 53%. The projected CAGR for the next 3 years is 17%.
What is the Gross Profit forecast for Karyopharm Therapeutics Inc?
Projected CAGR
15%
The compound annual growth rate for Gross Profit over the next 3 years is 15%.
